Some pharmacoeconomic aspects of epilepsy in adult patients

Authors

DOI:

https://doi.org/10.24959/cphj.20.1535

Keywords:

epilepsy, pharmacoeconomics, cost of illness, direct medical costs, non-medical costs, human capital index

Abstract

According to some publications, epilepsy accounts for 0.6 % of the global burden of diseases, and the cost of treatment of one patient with epilepsy reaches 88.2 % of the gross national product per capita. All this determines a great importance of pharmacoeconomic aspects in the treatment and life of these patients.

Aim. To perform pharmacoeconomic calculations for patients with epilepsy; to assess the following indices: cost of the disease, the human capital index, the realized human capital, a percentage of the human capital implementation, direct and indirect medical costs, a percentage of direct medical costs.

Materials and methods. The analysis was carried out on the basis of a sample from 74 patients (including 31 male and 43 female patients) with the average age of 36.99 ± 1.10 years old, who lived in Kharkiv or the Kharkiv Region.

Results. It has been found that the treatment of epilepsy inUkraine is rather expensive. The general cost of the disease is just over 100,000 UAH per year for a patient (approximately 3,500 US dollars). The most part of this cost consisted of indirect costs (73 % of the general cost of the disease on average). Indirect costs depend directly on the presence of seizures; patients, who have no seizures for a long time, have significantly lower indirect costs. All the indices of costs are the highest in a symptomatic form of epilepsy and the lowest in its idiopathic form. Among clinical parameters, the most significant ones for the formation of the cost of the disease were mental health disorders in epilepsy, especially dementia as a result of epilepsy.

Conclusions. The study performed shows that it is appropriate to use high-cost drugs, which result in compensation of the disease, ever from the economic point of view, not to mention social and medical aspects. In addition, the successful therapy with achieving long-term control of seizures (in accordance with data from the International League Against Epilepsy, it is possible for 70 % of such patients) results in an increase of a part of the realized human capital, i.e. in an appropriate socialization of these patients.

Author Biographies

A. Ye. Dubenko, SI “Institute of Neurology, Psychiatry and Narcology at the NAMS of Ukraine”

Doctor of Medicine (Dr. habil.), professor, leading researcher of the Department of Child Psychoneurology and Paroxysmal States

S. O. Sazonov, SI “Institute of Neurology, Psychiatry and Narcology at the NAMS of Ukraine”

Candidate of Medicine (Ph.D.), senior researcher

D. O. Kutikov, SI “Institute of Neurology, Psychiatry and Narcology at the NAMS of Ukraine”

laboratory assistant of the Department of Autoimmune and Degenerative Diseases of Nervous System, Center of Multiple Sclerosis

O. Ye. Kutikov, SI “Institute of Neurology, Psychiatry and Narcology at the NAMS of Ukraine”

Candidate of Biology (Ph.D.), associate professor; academic secretary

T. M. Kolesnik, SI “Institute of Neurology, Psychiatry and Narcology at the NAMS of Ukraine”

teacher of sociology, acting head of the Department of Scientific Management of Neurological and Psychiatric Care, Patent and License Work and Informational Provision

References

World Health Organization (2015). Sixty-eighth world health assembly. Resolutions and decisions annexes. Geneva. Available at: https://apps.who.int/gb/ebwha/pdf_files/WHA68-REC1/A68_R1_REC1-en.pdf

Thomas, S. V., Sarma, P. S., Alexander, M. et al. (2001). Economic burden of epilepsy in India. Epilepsia, 42, 1052–1060.

Ministerstvo okhorony zdorovia Ukrainy. (2014). Nakaz Ministerstva okhorony zdorovia Ukrainy vid 17.04.2014 № 276 «Unifikovanyi klinichnyi protokol pervynnoi, ekstrenoi, vtorynnoi (spetsializovanoi) ta tretynnoi (vysokospetsializovanoi) medychnoi dopomohy». zakon.rada.gov.ua. Available at: https://zakon.rada.gov.ua/rada/show/v0276282-14#n22.

Dubenko, A. Ye., Smolanka. O. Ye., Kutikov. D. O. et al. (2019). Ukrainskyi visnyk psykhonevrolohii, 27 (4 (101)), 10–15.

Iakovlieva, L. V., Bezditko, N. V., Herasymova, O. A. (2009). Farmakoekonomika. Vinnytsia: NOVA KNYHA, 208.

Iakovlieva, L. V., Bezditko, N. V., Herasymova, O. A. (2014). Farmakoekonomika. Kharkiv: NFaU, 123.

Ministerstvo finansiv Ukrainy. (2019). Serednia zarplata v Ukraini. Available at: https://index.minfin.com.ua/ua/labour/salary/average

Pensiinyi fond Ukrainy. (2019). Pensiine zabezpechennia u 2019 rotsi. Available at: https://www.pfu.gov.ua/tr/44327-pensijne-zabezpechennya-u-2019-rotsi/

Pensiinyi fond Ukrainy. (2019). Rozmir pensii. Available at: https://www.pfu.gov.ua/33135-rozmir-pensij-po-invalidnosti/

Derzhavna sluzhba statystyky Ukrainy. (2017). Tablytsi narodzhuvanosti, smertnosti ta ochikuvanoi tryvalosti zhyttia. Kyiv, 167.

Kompendium 2019 – likarski preparaty. (2019). Kyiv: MORION. Available at: https://compendium.com.ua/

Systema doslidzhennia rynku «PharmXplorer». (2020). Proxima Research. Available at: http://pharmstandart.com.ua/

Ministerstvo finansiv Ukrainy. (2020). Prozhytkovyi minimum v Ukraini 2020. Available at: https://index.minfin.com.ua/ua/labour/wagemin/

Published

2020-09-03

Issue

Section

Clinical Pharmacology and Pharmacotherapy